LSM12

Across TCGA pan-cancer cohorts, LSM12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LSM12 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LSM12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LSM12 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and OV are the cancer types where LSM12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.986	0.617	<.001	30	view →
PDAC	DFS	Quartile	III,IV	0.465	0.979	.010	11	view →
OV	DFS	Median	All	0.870	1.000	.045	4	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.875	.032	4	view →
CCRCC	OS	Quartile	III,IV	0.836	1.000	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LSM12–HNSC (DFS)

Open the HNSC breakdown →